Actuate Therapeutics was already keeping its planned IPO on the modest side, but the cancer-focused biotech has now lowered those expectations even further.

A doomed merger sent Infinity Pharma filing for bankruptcy last year. Now, the other half of that ill-fated deal is facing its end as well.

GRO Biosciences has ended the week with an extra $60.3 million in the bank, which the protein therapeutics-focused biotech will use to push its lead gout treatment into clinical trials.

Exscientia has taken full ownership of its oral CDK7 inhibitor candidate, buying out partner GT Apeiron for $20 million. The AI-enabled biotech plans to advance the molecule into a breast cancer combination trial.

The breakout success of GLP-1 drugs by Novo Nordisk and Eli Lilly has persuaded many of their Big Pharma peers to enter their own newly acquired candidates into the obesity race. But don’t expect Novartis to be joining them anytime soon.

The FDA has scotched Agenus’ plans to seek accelerated approval for a colorectal cancer combination, prompting the biotech to look into partnering to fund the phase 3 required to reach the market. Shares in Agenus fell 38% to around $11 in premarket trading.

Despite an FDA green light for the use of animal testing alternatives in drug development, regulatory concerns may be keeping the industry from embracing them, data collected by the R&D organization Pistoia Alliance suggests.

Now operating on its own, Grail is moving forward with large-scale clinical trials for its Galleri multi-cancer early detection blood test, as it ultimately aims to secure a premarket approval from the FDA and greater adoption worldwide.

SK Biopharmaceuticals has followed through on its promise to place big bets in a bid to become Asia’s radiopharma leader. The Korean biotech got the ball rolling by striking a $571.5 million biobucks deal to license a drug candidate in development at Full-Life Technologies.